Evidence map›Paper›PMID 36579994›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.

Heba E Abdelaziz, Nadia El-Guendy, Enas M Radwan, Sabry K Sharawi, Motawa E El-Houseini, Abdel-Hady A Abdel-Wahab

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Heba E AbdelazizDepartment of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt.
Nadia El-GuendyDepartment of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0002-0770-3740
Enas M RadwanDepartment of Clinical Pathology, National Cancer Institute, Cairo University, 1 Kasr El Eini Street Fom ElKhalig, 11796 Cairo, Egypt.
Sabry K SharawiDepartment of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt.
Motawa E El-HouseiniDepartment of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt.
Abdel-Hady A Abdel-WahabDepartment of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0002-5110-2600
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesTranscatheter chemoembolization (TACE) is the recommended therapy for intermediate stage hepatocellular carcinoma patients. Unfortunately, one of the main reasons for its failure is the emergence of multidrug resistance (MDR). Therefore, this study explored the possibility of using MDR-related miRNA as a response biomarker in HCC patients treated with doxorubicin drug-eluting bead TACE (DEB-TACE). PATIENTS AND

methodsQuantitative real-time polymerase chain reaction (qRT-PCR) was employed to evaluate the expression level of 14 MDR-related miRNAs in doxorubicin-resistant HepG2 cells (HepG2/Dox) developed by single-dose of doxorubicin mimicking the situation of liver cells surviving TACE. The sera level of miR-223-3p, which was the most significantly downregulated in the HepG2 cells, was determined in 60 primary HCC patients undergoing TACE. Restoring miR-223-3p in HepG2/Dox cell line was achieved by its mimic transfection. Cell sensitivity was measured by SRB assay. Cell apoptosis and doxorubicin uptake were assessed by flow cytometry. The expression of miR-223-3p target protein, P-glycoprotein, was evaluated using qRT-PCR and western blotting.

resultsWe detected a significant downregulation of circulating miR-223-3p in patients non-responders to TACE treatment compared with responders. The expression of miR-223-3p was markedly decreased in resistant HepG2/Dox cells compared to the parental control. In addition, the expression of miR-223-3p was found to be inversely correlated with P-glycoprotein expression thus confirming the role of miR-223-3p in MDR. Furthermore, overexpression of miR-223-3p suppressed P-glycoprotein which promoted cellular uptake of doxorubicin and increased apoptosis.

conclusionsOur data suggest a potential role for miR-233-3p as a prognostic as well as a therapeutic target for HCC.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsMicroRNAsATP Binding Cassette Transporter, Subfamily BDoxorubicinHumansPrognosisATP Binding Cassette Transporter, Subfamily BDoxorubicinMicroRNAsMIR223, humanDEB-TACEDoxorubicin Drug resistanceHepatocellular carcinomaMicroRNAp-glycoprotein

Identifiers

PMID36579994
PMCPMC9971467
OpenAlexW4313328137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.